QuantumRebel, I was about to answer your question on the NWBO PR coinciding with the release of a UK game changing regulatory announcement, but then I remembered Doc Logic’s comment that timing can be tricky.
I do think the UK wants to synchronize major game changing announcements to coincide with an approval of DCVax-L. The UK and MHRA already communicated they want to be the “global first choice for clinical trials” via “agile regulations”. Logically they will want to showcase a high-profile success story like DCVax-L to prove the model works.
I also suspect the UK wants to release their final guidance on ECAs and RWEs alongside a DCVax-L approval.
- Why? To synchronize the policy with a showcase example of success
- Do they have to? No. The MHRA already published the Complex Innovative Designs (CID) framework (effective 1/15/26). That is the formal legal guidance to deviate from traditional randomized trials and assess designs like ECAs. IMO it has more impact to publish that all together.
- So why the wait? Speculating… but it might not be a “delay” of ECA guidance or DCVax-L internal approval, but rather labeling negotiations.
- Label negotiations? If, in addition to GM, they are discussing a Conditional Marketing Authorization (CMA) that covers a broader range of malignant gliomas with Poly-ICLC as an adjuvant, those labeling and post-marketing condition talks could be complex.
I am thinking possibly labeling because under the new 2026 Type II Complex Variations mechanism, the MHRA is leaning into CMAs where there is available strong, safety, efficacy, and RWE data. Reminder, we have exactly that, with the UCLA Phase 2 trial (DCVax-L + Poly-ICLC: Used in malignant glioma). https://www.nature.com/articles/s41467-024-48073-y
So without speculating on a date, maybe the approval is simply waiting to align with events.
The key point is the NHS and UK is focusing on the future of “personalized” medicines. I have no doubt, DCVax-L is the 800-pound gorilla. It is the most clinically advanced personalized DC therapy available. Between the new GCP rules, the ECA guidance, and the UK's push for global leadership, too many things are lining up.
Baxers, Thanks for finding that info. I am thinking the same.
So it seems next week is highly likely. Maybe the Guidance on RWE and External Controls could just possibly be published at the same time (it is now due since the public comment closed on July 14th and it usually takes 6 months to publish). And just just there is a fleeting chance that along with all this the MHRA could make an announcement of....
Illustration only DCVax-L gets approved for GBM and wants to expand into Prostate cancer using adjuvants: Poly-ICLC + CKM regimen.
Optimal approach: Test 2 dual-combination protocols in parallel, not in triple-combo directly. - Path A: DCVax-L + Poly-ICLC for prostate cancer - Path B: DCVax-L + CKM regimen for prostate cancer Once CMAs granted, physicians can legally combine all 3 off-label. Eventually, RWE follows.
Background Platform consolidation: DCVax-L and Roswell trials DCs use the same fundamental DC engine and priming logic. As such CKM as an adjuvant to Roswell’s DC supports that it will also work with NWBO’s DC.
Continuing: The MHRA’s new Type II Extended Complex Variation mechanism is a game changer to obtain Conditional Marketing Authorisation (CMA) via label extensions, but not all therapies benefit equally. The DCVax-L Platform has a special advantage of being an adaptive platform (and Flaskworks) over other biologics that are fixed molecules. Below are my thoughts. If I am right, this is major for NWBO.
Advantage of adaptive platform over standard biologic drug Using Keytruda (pembrolizumab), known as the “king of agnostic” therapies, to illustrate.
Keytruda is drug-based - Drug: a “fixed” monoclonal antibody, therefore every new cancer indication requires a new Phase 3 to prove safety/efficacy in that environment. - Not truly agnostic: Agnostic only for specific mutations (like MSI-H, dMMR) - CMA expansion path: “Our Ph 2 data is so good in Ovarian cancer. Give us CMA now. We will finish the Ph 3 trial later.” - Disadvantage: Ph 3 trials are expensive and can fail (pass/fail)
DCVax-L is adaptive and platform-based - Process: The MM Master File "pre-clears" the Flaskworks system. The MHRA focuses on the consistency of the process, not just the tissue type. - Truly agnostic: uses the patient’s own tumor lysate (personalized). It is agnostic because it captures all the antigens (adapts to the new target) - CMA expansion path: “RWE shows DCVax platform works in Ovarian cancer. Give us CMA now. CMA will provide continual RWE.” - Advantage: Secures a CMA based on surrogate signals (IFR/RWE), then provides the data while selling the product.
Other points - The 2026 regulations (SI 2025/87) were specifically designed for decentralized, POC, and “personalized medicine” mfg, and as such the MM Master File is integral. - Keytruda is a mass-produced biologic and does not - Whereas NWBO does and has a special advantage in this new MHRA fast track system.
Eagle, I know your question about DCVax-L as SOC for all solid tumors was rhetorical, but it is an important thought question as we know the DCVax platform has a great potential in that direction. So in sharing with that thought:
SOC treatment definition roughly: - A consensus driven process - SOC is not an official declaration - Means the treatment is included in an official “clinical practice guidelines” publication, ie something issued by European Association of Neuro-Oncology (EANO) - Means there is affordability or broad insurance coverage, ie reimbursement by UK's NHS
I do believe the pieces will converge for that to be possible, but let’s see. For now, I am looking for these to emerge: - GBM approval, Flaskworks, and Type II Variation applications for label extensions into other cancer indications - DCVax-L pricing negotiations (whether price elasticity and pay-per-dose becomes part of it) - Behind the scenes support (feedback from KOLs, 70 authors/oncologists from DCVax-L trial JAMA who are all advocates for their patients).
Attilathehunt, Yes the regulatory pathway is effective now, as of 1/15/26. With DCVax-L approval for GBM, NWBO can apply for label extensions under Type II Variations. There seems to be an especially great fit between the DCVax platform + Flaskworks + IFRs and/or existing clinical data and this new pathway to get label expansions into new indications.
Continuing…. The “bridge” towards tumor agnostic Under this Jan 2026 massive MHRA regulations update, the new Type II Extended Complex Variation mechanism enables the DCVax-L platform to get Conditional Marketing Authorizations (CMA) for additional cancer indications via a label expansion pathway.
Key translation: NWBO can commercialize rapidly, saving years and money by bypassing the traditional requirement for new, stand-alone Phase 2/3 pivotal trials for every indication. This creates a regulatory superhighway for the DCVax platform.
Big picture: the DCVax Platform profile - Supercharged dendritic cells (the “general” of the immune response) - Vaccine-like immunotherapy (as opposed to a drug) - Truly autologous (both DCs and antigens are from self) - Truly personalized (target ALL the specific antigens) - Systemic efficacy (mounts a holistic immune response) - Durable response (long-term immune memory against recurrence) - Tumor and stage agnostic (a broad-spectrum cancer vaccine) - Low-cost, scalable manufacturing (Flaskworks automation) - IP moat (dominant protection around DC-based priming and immunotherapy)
- Real-world-data (RWD): A decade of data from German Hospital Exemption (2014), UK “Specials”, and “Information Arm” of Ph3.
The “Bridge” (platform-based logic) - Normally must prove “consistency” via new trial for every new cancer - The Modular Manufacturing (MM) Master File (SI 2025/87) allows the Flaskworks system to confirm mfg and product consistency across different indications. - That means regulatory "pre-clearance" for the CMC/Quality section, which would otherwise require new trial data. - The NHS Individual Funding Request (IFR) for “Murcidencel” (broad “Cancer” category) can provide access, funding, and RWE to continually fuel new CMAs.
High level, roughly - Time savings: Bypass 7–10 years Phase 3 trials; replaced by 90-120 days Type 2 Variation reviews. - Financial savings: Save 100’s of $M per indication by eliminating redundant trials - Market capture: Time-to-market is accelerated by years, reaching “tumor agnostic” thru iterative steps - Risk mitigation: Binary (pass/fail) trial risk is replaced with “iterative progress”, collecting data while the product is being sold under a CMA.
Maverick, Thanks for sharing your story. Life has many twists and turns. Gandalf the Gray through adversity becomes Gandalf the White. So it is with paths and the journeys life takes us on, and everyday is trying to become better for it. Same for NWBO. Glad to be on this journey together.
Acelerator, Great post and thanks for sharing that lovingly personal story.
On that point of FUD and the negative impact it tries to inflict:
No one is immune to continual manipulative FUD posts. So here are my words for due diligence, the tether to reality, and the will to not succumb to gaslighting.
As this is the 25th anniversary of Lord of the Rings movies, Samwise Gamgee said, "I can't recall the taste of food, nor the smell of the grass, nor the touch of the flowers. But I do know that I can't go on without you." Nothing grand, just genuine perseverance.
Does a 1st-generation immigrant, not knowing the language, risk everything by opening a small restaurant? I would say it is mitigated by the trust in their own perseverance, the will to put in as many hours as needed to make it work out.
Do the richest people in America become so, by concentrating risk into a single company? I would say it is mitigated by deep understanding, devoting all their time and energy into running the business.
Do VCs get rich automatically? I would it is a deliberate process of continual due diligence. Pick the 10 best opportunities from 1,000. They don't diversify into the top 50. And it is not just the top 10 that matter either. It is the continual process of “knowing” and adding to the winners and cutting the losers. In the end, maybe only 2 or 3 truly succeed, but they create the extraordinary returns.
Do NWBO Retail investors have to succumb to gaslighting? I don’t believe so. - It is about understanding that disrupting the medieval model, of toxic drugs that do not cure the underlying cancer, is hard. - To realize over 400 clinical trials in GBM failed in the last 15 years. Only one, DCVax-L, has resulted in a successful global Phase 3 clinical trial. - To recognize the intrinsic value and ecosystem being created (DCVax platform, IP/patents, acquisition of Advent and Roswell patents, oncologists, etc) - To ignore the obvious manipulation FUD posts - Knowing continual due diligence is both the best shield and best wealth strategy.
ATLnsider, Agree. The combination of DCVax-L having the qualities of a cancer vaccine (as opposed to risk for severe toxicity drugs) and being tumor-agnostic plus the new MHRA mechanism to bridge towards conditional marketing authorization is no small matter, repeat, no small matter. I am very optimistic for this.
Flipper, I am hoping for this too. Also the new hires could just be the matter of the company preparing for the initial base layer expectations of approval and commercialization, but I believe LP is receiving many other signals beyond approval, ie both seen (IFR mechanism, Jan 20th variations...) and unseen (feedback from KOLs, 70 authors/oncologists from DCVax-L trial JAMA who are all advocates for their patients). These would be signs of demand for DCVax-L and for the asap ramp up and expansion of production capacity.
The Unity Campus lease in 2025 is another signal, maybe 10K sq feet to house R&D / office likely, but in the end it is to also enable the Sawston facility to apply more of its space towards production capacity. Lots of irons in the fire.
This is a follow up to my 11/2/25 post, the idea for a compromise authorization, a bridge mechanism for DCVax-L getting tumor-agnostic approval.
As part of its massive regulations update, the MHRA added the new Variations Guidance on 1/15/26. On 1/20/26, the MHRA added a new section within it called “Variations to add a new therapeutic indication”. This new text creates a regulatory pathway that could be that “bridge” via continual label expansion. I am not saying the MHRA will or will not do so, just pointing out that it appears now it can.
Variations to add a new therapeutic indication These variations will usually be classed as “Type II extended complex” because of the nature and extent of the supporting clinical data required to verify the safety and efficacy of the product in the proposed new indication and demonstrate that the balance of benefit and risk is positive.
In certain circumstances where comprehensive data are not yet available to support the safety and efficacy of the proposed new indication, the MHRA may decide to grant the variation but use its powers in Paragraph 15 of Schedule 10A of the HMRs to amend the decision to grant the original marketing authorisation, and consequently the terms of the MA, to convert it to a conditional marketing authorization [CMA] (if it is not already one). It will be subject to associated specific obligations, and reassessment on annual renewal, until comprehensive data are available.
The MHRA may make this decision after discussion and agreement with the marketing authorisation holder, if all the following criteria are met:
- the benefit-risk balance of the proposed new indication is positive; - it is likely that the marketing authorisation holder will be able to provide comprehensive data after grant of the variation; - the proposed new indication fulfils an unmet medical need; - the benefit to patients of the medicine’s immediate availability for the new indication is greater than the risk inherent in the fact that additional data are still required.
Thoughts: 1. The "Type II extended complex" is a mechanism that can convert an existing license into a CMA for that new indication, ie a bridge towards tumor-agnostic.
2. The MHRA grants the GBM license as "Standard" and then apply the mechanism to grant another tumor indication as "Conditional" based on the existing clinical/RWE data, and contingent on future data collection.
3. Reminder: we already have a mechanism for obtaining RWE across multiple cancer indications. DCVax is registered as Murcidencel with the broad label “Cancer” under the NHS’s Individual Funding Request (IFR) mechanism. This is an existing pathway for DCVax-L to be accessed and funded for most, it not all, cancer types in the UK. https://www.england.nhs.uk/publication/nhs-england-drugs-list/
HyGro, It’s not me saying you are wrong. It is the MHRA’s own Draft Guideline on External Control Arms (section 11) saying you are wrong.
Your statement “require pre-trial design and mutual agreement” is wrong. There is NO requirement. 11. A trial with an ECA is not the preferred clinical trial design as a fully powered randomized controlled trial (RCT) should be used if possible. However, any regulatory decision is based upon the data presented in the submission, and if those data are sufficiently convincing then a positive decision can be reached, even if alternative approaches may have ideally been preferred. Therefore, there is no general scenario where the use of RWD external controls is explicitly ruled out.
MHRA has an additional nail against your statement. 8. While the guideline is specifically aimed at sponsors planning to use RWD ECAs, many of the general principles would be relevant for external controls drawn from other sources, such as previously completed clinical trials. MHRA is also interested in engaging with sponsors who have proposals for using such data sources.
Your statement “Let’s see if MHRA violates their new guidance with the DCVax-L review.” FYI, if the MHRA publishes guidance, by definition, they are not violating it. They are following it.
The high-level reason PR 1/13/26, which I already posted from the chain you are replying from. The MHRA’s set of reforms is aimed at helping patients access new cutting-edge treatments more quickly “with faster assessments and agile regulation”. That is their goal.
JED, The MHRA’s Complex Innovative Designs (CID) is the umbrella and platform for including external control arm trial data, meaning External Controls and Real-World Evidence are core components of "Complex Innovative Designs."
- In the CID section I shared with everyone, the MHRA officially included a link there. - Click that link: “Blagden et al. Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement. Br J Cancer 122, 473-482 (2020).” That is the technical basis for what the MHRA will use. - Then click: “Table 1 Types of CID trials” - At the bottom of the table, you will see “(i) Descriptions specify the comparison of experimental arms to a control arm C, but designs can include experimental arms that would be compared to historical controls;”
I would associate the term “complex innovative designs” as a structure that includes ECA and RWE.
Exwannabe, You are downplaying the implications of MHRA's new framework's application to NWBO. That doesn't make sense. - the MHRA does not just regulate the start of trials, it covers the entire lifecycle of a medicine. - the new rules is stating what kind of data the MHRA now considers valid for a licensing decision. It is not just for new applications.
NWBO is just starting to make a move. These new regulation will apply to DCVax-L phase 3 trial and new trials in the future. The better read is these long awaited updates in regulations are very helpful for NWBO.
A number of long awaited MHRA updates on their portal went live this week, coinciding with JP Morgan Biotech conference. They are active and effective immediately:
continued: An optimistic scenario / hypothesis, maybe… but if stars align, we may see a “showcase approval” in the next 48 hours.
Assume: a coordination between MHRA and NICE to provide a landmark win for the UK delegation in SF JPM conference, to showcase DCVax-L as an approval success story.
If so, the sequence could look like this: - Step 1: Publish the standalone "Guidance on the Use of Real-World Data and External Controls” Jan 14/15th - Step 2: The NICE Committee B meeting meets January 14, 2026. TBD but if DCVax-L the “showcase” then this gets voted on, ie vote on DCVax-L on cost-effectiveness pricing. - Step 3: MHRA grants MA approval of DCVax-L and NICE simultaneously release its cost-effectiveness guidance.
Data points: 1. J.P. Morgan Healthcare Conference (JPM) approaches (12–15 January 2026): “The reforms are being highlighted as MHRA Chief Executive Lawrence Tallon attends the J.P. Morgan Healthcare Conference in San Francisco this week, alongside Health Minister Zubir… The UK is setting out a clear offer: a country that is faster to start trials, open to innovation and built for growth.”
“UK is ramping up efforts to become a global first choice for clinical trials, as new figures published today (13 January)”
At center is an 800-pound gorilla. The Institutions are built-in structural demand to buy NWBO stock once NWBO gets approval. They will then begin crossing the line. ~0% now but normally increase to 70% over time. As Gary explains, it is to get the larger $ gains, as opposed to the larger % gains, even though they are starting at higher prices. They move the central equilibrium.
We Retail Long investors are on the other side. Sharing due diligence by knowledgeable and generous posters on IHub here make this situation very unique. We see things differently and are investing with hard-earned savings (as opposed to Funds who do so with other people’s money).
Thoughts - Time-invested is the osmosis of wisdom, due diligence, and the understanding of signs and long-term opportunities. - Timing is employing the smarts of juggling risks and opportunity, to catch it at the right time.
The signs are here: Nov’25 CHM meeting, UK GCP/ECA Jan’26, 2nd MIA (human basis) Dec’25, ASM reiterating Advent acquisition, start construction of C suite labs, and the $1M equipment purchase.
The intersection of long-term tectonic plates: - Retail Longs holding shares - Institutions are built-in structural demand to buy - DCVax tech platform that disrupts the cancer therapy landscape
Doc logic, Here is a joke response to your question: “China has more than 90,000,000 more men than women. Care to figure out how this pans out in the world we see around us now?”
Given your NWBO context, this is how AI processing can come to an alternate conclusion.
Technical Analysis: All gaps eventually get filled. DCVax-L Phase 3 trial: Everyone is living longer. Technology: Flaskworks’ personalized and automated systems. AI and robots are replacing humans.
Miltong, Well said. The MHRA has a schedule, and it is January 2026 that they will release their “most significant update to the UK clinical trials landscape in 20 years”. And this is the month that I believe they will want to approve DCVax-L simultaneously and showcase them as a high-profile success story.
On waiting, who is not vulnerable to waiting, to time?
This thing all things devours: Birds, beasts, trees, flowers; Gnaws iron, bites steel; Grinds hard stones to meal; Slays king, ruins town And beats high mountain down.
But for Longs whose due diligence sees a major unicorn investing opportunity, I will just say what we all already know. Uncertainty of timing is a natural part of investing and particularly in disruptive companies and investments. That is why “time invested” not “timing” is both the best shield and the best strategy, IMPO.
The typical signs that smart-money uses to eagle-eyes focus into, before others do, in other investments, I believe we Longs have already identified here before the Institutions have. I see a convergence of events that suggest January 2026 is the window for DCVax-L approval. Again, if I am wrong, so be it, but I do sense movement in the air:
- (Regulatory) The November 27/28, 2025 CHM meeting reviewing DCVax-L. Add 4 to 8 weeks to convert that into a Marketing authorization.
- (Policy) Final ECA guidelines published within and/or alongside UK adopting new GCP Guidelines scheduled for January 2026. The purpose would be alignment and cite the finalized ECA rulebook altogether.
- (Licensing) The MHRA issues (Advent, NWBO owned) a second MIA 12/15/2025 under “human legal basis”, I believe to certify Flaskworks as a new and additional commercial process (ie MIA license update comes first, then GMP inspection later).
- (Physical) 12/29/25 ASM reiterated the start of construction of Grade C suite and their $1M specialized equipment buy. It strongly hints that Flaskworks has been in the review process and has achieved a "design freeze" for the GMP units. That is why they made those financial commitments.
Flipper, You asked about the ECA timeline. I see 4 indications that converge and point to this month, January 2026, as being the MHRA publishing date for the final ECA Guidelines.
1. UK-Specific External Control Arms (ECA) Guideline Finalization - MHRA published draft: May 20, 2025 - Consultation period closed: July 14, 2025 - Per AI, finalization typically takes 4–6 months to process stakeholder feedback.
3. UK is integrating with international standards, the ICH E6(R3) release - Annex 2 of the GCP (ICH E6 R3) specifically covers trials with innovative designs like RWD and ECAs. - That means this falls under the January 2026 release as well
- “The new draft guideline, titled Annex 2, is an additional document in the portfolio that includes the GCP Principles and Annex 1. It is intended to support ‘appropriate and proportionate application of GCP’ to trials that incorporate so-called decentralised elements, pragmatic elements and/or real-world data (RWD)." https://www.goodtrials.org/annex2/#:~:text=The%20new%20draft%20guideline%2C%20titled,%2Dworld%20data%20(RWD)
Gary, All good points. I always remember you making the point that "major institutions will want to buy in for share price growth". It is a lesson we all should keep in mind, that Retail look for % gains but Institutions focus on gross price gains. The lesson being that, although % gains "look" better early (when penny prices can multiply, eg 5X, 10X), the real gains (wealth) are made in the price appreciation of $$$ dollars later on.
JED, Not explicitly named in that single sentence, but I believe they are all technically inseparable and will be announced together. The GCP E6(R3) is the “umbrella” framework for ECAs, ie the rules for trials for innovative designs like RWE and ECAs. (source)
It is refreshing we Retail investors have a chance to invest in a “unicorn company” early on, before the typical scenario where financial investors “knew first”, took their positions, and have pushed the prices up into FOMO land already. Everything is about due diligence, and I think finally, for once, the roles are reversed.
The signs typical smart money sees early on, I believe we Retail are seeing it now, a convergence of events that suggest January 2026 is the window for DCVax-L approval. I sense a movement in the air:
- (Regulatory) The November 27/28, 2025 CHM meeting reviewing DCVax-L. Add 4 to 8 weeks to convert that into a Marketing authorization.
- (Policy) The MHRA scheduled January 2026 to release the “most significant update to the UK clinical trials landscape in 20 years”, publishing their new and final GCP and ECA guidelines. I believe they want to approve DCVax-L simultaneously to showcase them as a high-profile success story and that the UK is “officially open for biotech business”. (source)
- (Licensing) The MHRA issues a second MIA 12/15/2025 under “human legal basis” to certify this new and additional commercial process (Flaskworks).
- (Physical) 12/29/25 ASM reiterated the start of construction of Grade C suite and their $1M specialized equipment buy. It strongly hints that Flaskworks has been in the review process and has achieved a "design freeze" for the GMP units. That is why they made those financial commitments.
Sidenote: Today 1/5/26, the MHRA added a new Chief Medical and Scientific Officer, Professor Jacob George. (source)
Eagle, Agree. I see NWBO is becoming a BP platform company and creating an ecosystem to be a "dominant franchise".
1. Franchise = Proprietary Infrastructure - Typical biotechs sell single drugs. - NWBO’s owns proprietary DC therapy ecosystem, ie mfg IP, patents, and “blueprints” to scale.
2. Vertical Integration = Optimize gross margin % - Typical biotechs outsource mfg to CMOs, losing 40–60% of margin - NWBO owns the mfg / Advent (key), also enables continual process and cost-reduction improvements
3. Price Elasticity (“safety” advantage) - Most BP drugs have a toxicity barrier, which limits drug label and addressable market - DCVax-L’s vaccine-like safety and agnostic nature allows for a much larger market (multi-tumor) - High gross margins from owning Advent gives NWBO the price elasticity to negotiate optimal pricing
4. Intellectual Property Moat - In-licensing Roswell Park DC technology creates a “version 2.0” for the DCVax pipeline - If 1.0 is priming the immune system, then 2.0 is reprogramming the Tumor Microenvironment TME, to turn “cold” tumors “hot”.
5. Franchise as Strategic Footprint - As base-layer treatment or for combos like DCVax + Keytruda or DCVax + Poly-ICLC (similar to the Merck model) - The “Sawston Model” is a repeatable, proprietary, standardized system. NWBO can “copy-paste” these internal hubs around the world.
Sharpie, One possible reason for the MIA authorization under “Human” in both 2/27/25 and in 12/15/25 is because Advent additionally leased new space at Unity Campus. Adding an off-site lab expansion possibly requires an update to the MIA.
Another possibility is based on a previous hypothesis of mine. The second authorization could be for a second manufacturing process, Flaskworks, ie the initial, small-scale version. The flow of events in that scenario would be:
- 2/6/24 NWBO PR stated they were going to undertake final qualification and validation of the Flaskworks GMP units. - ~2024-2025, NWBO was possibly conducting an MHRA informal review of the initial version of Flaskworks validation data, making it near-ready by 7/23/25. - The MAA was then amended to include this Flaskworks validation data to leverage the new Modular Manufacturing framework (SI 2025/87) on 7/23/25. - The inspection was successful. - The MHRA issues a second MIA 12/15/2025 under “human legal basis” to certify this new and additional commercial process (Flaskworks). - This certification clears the way for the MHRA to issue the final MAA approval.
Ilovetech and Andrew, Thanks for this informative post. I like this part and a thought:
Excerpt
Murcidencel is not named like a single-cancer drug… Culturally, oncology still talks as if therapies “belong” to organs: a lung drug, a breast drug, a brain drug. That framing comes from cytotoxic chemotherapy and targeted inhibitors.
It does not reflect how immunology works…
… The maturation inputs can evolve, because what defines the product is the validated functional phenotype and outputs, not the historical cocktail used to reach them.
…
A persistent misconception is that INNs commoditize therapies. For platform ATMPs under strong IP and manufacturing control, the opposite holds.
Murcidencel’s INN amplifies NWBO’s strategic position, because it locks the generic identity of the platform to terrain NWBO already dominates with patents, exclusive licenses, and manufacturing control…
Using the murcidencel name forces convergence into NWBO-controlled space rather than allowing workarounds around it.
Thought experiment: For fun given the unique benefits of the dendritic cell therapy platform (Murcidencel), future branding and public consciousness terms that could evolve, similar to the term “Google it” (search it) and “Xerox it” (copy it) tied to the company:
“DC train it” – for cancer treatments, it would mean an initial DC vaccine dose first, to prime the immune system
“DC vaccinate” – for the prophylactic vision for cancer, as a vaccination, to gain robust immune memory for prevention.
Evanstony, That is why so many people love the Lord of the Rings, for its bravery, risking everything to do the almost impossible, to do good, and for the moments of friendship and loyalty (ie Samwise to Frodo).
You summarize it perfectly: “Some thought they were crazy to believe in a new world”. I agree it does take a certain “crazy” to change everything.
For NWBO we have an emerging unicorn company with the true potential to entirely change how cancer is treated and potentially cure cancer. Same point, great change takes time and sacrifice.
Linda Powers’ signature in everything she does is high quality and at gold standard levels. That is a double-edged sword for some. But sometimes that is precisely what is required to disrupt an entire landscape of incumbent and old ways. And now we are at the cusp of MAA approval for DCVax-L.
"The reasonable man adapts himself to the world: the unreasonable one persists in trying to adapt the world to himself. Therefore, all progress depends on the unreasonable man." ? George Bernard Shaw
JTaylor, I understand your reference. I will just say, the world pre-MAA approval is one of stealth because of regulators and because predators abound. But post-approval, the ecosystem becomes commercial, governed by an entirely different set of rules. Healthy optimism dominates that world, and we will all benefit too.
Flipper, As January marks the 25th anniversary of The Fellowship of the Ring, and we Retail Longs on IHub form a most unlikely fellowship of ragtag, hopeful retail investors, I shall respond in that light.
You speak of Father Time, a 3 RFI timeline, this riddle of the long MAA waiting. It is a thing that gnaws at patience, bites at resolve, grinds down due diligence, slays the investor, and beats down the good company. The long game that has defeated many otherwise strong handed longs.
That dark hour may yet come to be, but I do not believe that time is now.
For what I see is an age of chemotherapy passing. Great change, major progress, takes time. DCVax-L stands on the cusp of approval. And a dendritic cell revolution is about to begin.
We are approaching a moment in history where DCVax (platform and ecosystem) takes society out of a medieval period where today's cancer drugs do not cure the underlying cancer and into a renaissance period where a cancer vaccine possibly does.
Holistic medicine, personalized immunotherapy, and vaccine not drug, is the path towards the potential cure for cancer.
So I see Father Time as a signal. It is the compass pointing back to the Northwest (NWBO), even as the first light breaks in the East. GANDALF: “Look to my coming (MAA approval) on the first light of the fifth day, at dawn look to the East (MHRA).”
Whether MAA approval is December or January… Whether legal or naked, short or synthetic contracts, or any combination… It’s about the long game.
Fellow Retail Longs,
With regards to stock price, initial money flows and momentum, the most important thing for Retail Longs in aggregate is: - To support the stock price to $5/share (not selling) - So Institutional Investors can take over from there and push it up to $10/share and beyond (structural demand)
Accelerate the timeline: - The faster it goes to $5, the greater the momentum and speed to $10 - Against potential market manipulation, the best defense is a strong offense
Meaning: - The exponential gains will come from holding - Not from the loud gaslighting by disguised shorts to sell/trade
It’s still the same game: - Retail and Management ownership is ~99% - Approval means Institutional investors are built-in structural demand to buy shares (typically up to 70% ownership, over time) - Shorts remain trapped holding large quantities of mark-to-market liabilities - They need Retail to sell to cover - But Retail is not selling
So I ignore the loud voices to: - sell/trade - move on - settle for $2 or $3/share
Barnstormer, I like your post and given the back and forth in other people's posts, I just wanted to highlight an important thing you said, "Fact is I don't care whether manual or Flaskworks is the initial process used. I just want the MHRA to approve DCVax-L and move forward."
Let me add also that adding a new manufacturing process does not mean replacing. It just means adding. It means a company will have multiple approved methods for manufacturing. With demand likely far exceeding capacity for DCVax-L, both the manual (Grade B) and Flaskworks (Grade C/MM) processes will be fully used.
It is highly likely the same applies to a hypothetical amendment to the MAA that includes the Initial small-scale Flaskworks/Eden version under Modular Manufacturing (SI 2025 No. 87).
It would also be consistent with what GZ reportedly said, that initial commercial launch will be manual. It can be both simultaneously. It is normal stuff to have multiple approved systems.
Ilovetech and Andrew, Great post again. If I may...
This is where the historical parallels become unmistakable. Genentech industrialized antibody production. Amgen industrialized recombinant growth factors. Gilead industrialized antiviral synthesis. NWBO, improbably, found itself poised to industrialize dendritic cell instruction.
My poetic version: Medicine stands on the threshold of a renaissance. The time of medicine not curing the underlying cancer is about to give way to a medicine that does.
Genentech mastered the skill of cloning antibodies. Amgen honed the art of taming cellular growth. Gilead wielded the alchemy of silencing viral spread.
Yet those are skills, arts, and alchemy… tools in mortal hands. A sword means little to an untrained warrior. A single fish cannot sustain the hungry for long.
NWBO does what the world has long awaited. It teaches the immune system to learn, to remember, to heal.
Market Data 
Markets 
